{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:20:45Z","timestamp":1782840045238,"version":"3.54.5"},"reference-count":43,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Cancer Institute of the National Institutes of Health","award":["5 P01CA068484"],"award-info":[{"award-number":["5 P01CA068484"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.ejca.2011.03.022","type":"journal-article","created":{"date-parts":[[2011,4,22]],"date-time":"2011-04-22T21:42:07Z","timestamp":1303508527000},"page":"1373-1379","source":"Crossref","is-referenced-by-count":104,"title":["The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: A report from the Dana-Farber Cancer Institute ALL Consortium"],"prefix":"10.1016","volume":"47","clinical-trial-number":[{"clinical-trial-number":"nct00165087","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00165178","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00400946","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Lynda M.","family":"Vrooman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna S.","family":"Neuberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen E.","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara L.","family":"Asselin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma H.","family":"Athale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Clavell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter D.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara M.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric C.","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Laverdi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Michon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshall","family":"Schorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy L.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey J.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Lipshultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis B.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.","family":"Sallan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.ejca.2011.03.022_b0005","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","article-title":"Treating childhood acute lymphoblastic leukemia without cranial irradiation","volume":"360","author":"Pui","year":"2009","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2011.03.022_b0010","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1182\/blood-2007-09-112920","article-title":"Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95","volume":"111","author":"Moricke","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ejca.2011.03.022_b0015","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1365-2141.2005.05509.x","article-title":"Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial","volume":"129","author":"Mitchell","year":"2005","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.ejca.2011.03.022_b0020","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1470-2045(09)70228-1","article-title":"Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997\u20132004)","volume":"10","author":"Veerman","year":"2009","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2011.03.022_b0025","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/leu.2009.262","article-title":"Long-term results of the children\u2019s cancer group studies for childhood acute lymphoblastic leukemia 1983\u20132002: a Children\u2019s Oncology Group Report","volume":"24","author":"Gaynon","year":"2010","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.ejca.2011.03.022_b0030","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2006-06-027714","article-title":"Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia","volume":"109","author":"Moghrabi","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ejca.2011.03.022_b0035","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/leu.2009.257","article-title":"Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000","volume":"24","author":"Moricke","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.ejca.2011.03.022_b0040","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2","article-title":"A clinicopathologic analysis of adriamycin cardiotoxicity","volume":"32","author":"Lefrak","year":"1973","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2011.03.022_b0045","doi-asserted-by":"crossref","first-page":"b4606","DOI":"10.1136\/bmj.b4606","article-title":"Cardiac outcomes in a cohort of adult survivors of childhood, adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort","volume":"339","author":"Mulrooney","year":"2009","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.ejca.2011.03.022_b0050","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1517\/14656566.8.8.1039","article-title":"Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management","volume":"8","author":"Barry","year":"2007","journal-title":"Expert Opin Pharmacother"},{"issue":"10","key":"10.1016\/j.ejca.2011.03.022_b0055","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S1470-2045(10)70204-7","article-title":"Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial","volume":"11","author":"Lipshultz","year":"2010","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2011.03.022_b0060","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1200\/JCO.1997.15.4.1318","article-title":"Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer","volume":"15","author":"Swain","year":"1997","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2011.03.022_b0065","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1200\/JCO.1998.16.1.86","article-title":"Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas","volume":"16","author":"Lopez","year":"1998","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2011.03.022_b0070","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa035153","article-title":"The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia","volume":"351","author":"Lipshultz","year":"2004","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejca.2011.03.022_b0075","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1200\/JCO.2005.02.3879","article-title":"Dexrazoxane-associated risk for acute myeloid leukemia\/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin\u2019s disease","volume":"25","author":"Tebbi","year":"2007","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2011.03.022_b0080","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1200\/JCO.2007.12.2481","article-title":"Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane","volume":"26","author":"Barry","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2011.03.022_b0085","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1182\/blood-2006-09-045369","article-title":"Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01","volume":"110","author":"Zhou","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ejca.2011.03.022_b0090","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/pbc.22225","article-title":"Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia","volume":"54","author":"Vrooman","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2011.03.022_b0095","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1182\/blood-2009-09-245951","article-title":"Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia","volume":"115","author":"Silverman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2011.03.022_b0100","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of competing risks","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"key":"10.1016\/j.ejca.2011.03.022_b0105","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"8","key":"10.1016\/j.ejca.2011.03.022_b0110","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/jnci\/93.8.618","article-title":"Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study","volume":"93","author":"Neglia","year":"2001","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.ejca.2011.03.022_b0115","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1200\/JCO.1995.13.3.603","article-title":"Subsequent malignancies in children and adolescents after treatment for Hodgkin\u2019s disease","volume":"13","author":"Beaty","year":"1995","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2011.03.022_b0120","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1002\/1097-0142(19881001)62:7<1364::AID-CNCR2820620721>3.0.CO;2-T","article-title":"Second malignancies after childhood Hodgkin\u2019s disease. The Memorial Sloan-Kettering Cancer Center experience","volume":"62","author":"Kushner","year":"1988","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2011.03.022_b0125","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJM199603213341201","article-title":"Breast cancer and other second neoplasms after childhood Hodgkin\u2019s disease","volume":"334","author":"Bhatia","year":"1996","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2011.03.022_b0130","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1200\/JCO.1997.15.6.2247","article-title":"Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin\u2019s disease. German-Austrian Pediatric Hodgkin\u2019s Disease Group","volume":"15","author":"Schellong","year":"1997","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2011.03.022_b0135","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/jnci\/95.13.971","article-title":"Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin\u2019s disease","volume":"95","author":"van Leeuwen","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.ejca.2011.03.022_b0140","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1200\/JCO.1993.11.2.209","article-title":"Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide","volume":"11","author":"Winick","year":"1993","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2011.03.022_b0145","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/leu.2009.252","article-title":"Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia","volume":"24","author":"Pui","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.ejca.2011.03.022_b0150","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/leu.2009.250","article-title":"Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia","volume":"24","author":"Conter","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.ejca.2011.03.022_b0155","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/leu.2009.258","article-title":"Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004","volume":"24","author":"Kamps","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.ejca.2011.03.022_b0160","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/leu.2009.256","article-title":"Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980\u20132001","volume":"24","author":"Mitchell","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.ejca.2011.03.022_b0165","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/leu.2009.259","article-title":"Long-term results of the Japanese Childhood Cancer and Leukemia Study Group studies 811, 841, 874 and 911 on childhood acute lymphoblastic leukemia","volume":"24","author":"Tsurusawa","year":"2010","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.ejca.2011.03.022_b0170","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1056\/NEJM199112123252402","article-title":"Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia","volume":"325","author":"Pui","year":"1991","journal-title":"N Engl J Med"},{"issue":"8763","key":"10.1016\/j.ejca.2011.03.022_b0175","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0140-6736(91)90490-G","article-title":"Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours","volume":"338","author":"Pedersen-Bjergaard","year":"1991","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.ejca.2011.03.022_b0180","doi-asserted-by":"crossref","first-page":"10629","DOI":"10.1073\/pnas.1832879100","article-title":"Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187","volume":"100","author":"Classen","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.ejca.2011.03.022_b0185","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF00686403","article-title":"Doxorubicin inhibits human DNA topoisomerase I","volume":"30","author":"Foglesong","year":"1992","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.ejca.2011.03.022_b0190","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1200\/JCO.1999.17.2.569","article-title":"Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins","volume":"17","author":"Smith","year":"1999","journal-title":"J Clin Oncol"},{"issue":"Suppl. 5","key":"10.1016\/j.ejca.2011.03.022_b0220","first-page":"ECR09","article-title":"Two consecutive immunophenotypic switches in a child with MLL-rearranged acute lymphoblastic leukemia","volume":"91","author":"Germano","year":"2006","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.ejca.2011.03.022_b0200","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/leu.2009.261","article-title":"Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984\u20132001: a report from the children\u2019s oncology group","volume":"24","author":"Salzer","year":"2010","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.ejca.2011.03.022_b0205","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1200\/JCO.20.1.237","article-title":"Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01","volume":"20","author":"LeClerc","year":"2002","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2011.03.022_b0210","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/leu.2009.253","article-title":"Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985\u20132000)","volume":"24","author":"Silverman","year":"2010","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.ejca.2011.03.022_b0215","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/cncr.23988","article-title":"Acute leukemia as a secondary malignancy in children and adolescents: current findings and issues","volume":"115","author":"Hijiya","year":"2009","journal-title":"Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804911002048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804911002048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T01:19:14Z","timestamp":1637543954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804911002048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0959804911002048"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2011.03.022","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}